Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JANUS: Atacicept in IgA Nephropathy
NCT02808429Phase 2Terminated
- Sponsor
- EMD Serono
- Start
- Jan 2017
- Primary completion
- Feb 2020
- Modality
- Fc-Fusion Proteins
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of atacicept in IgA nephropathy (IgAN) (3 arms), sponsored by EMD Serono. Primary endpoint: Percentage of Participants With Treatment-Emergent Adverse Events at 96 weeks. Started Jan 2017; status: terminated.
02
Drugs
atacicept
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT02808429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02808429.